Trip.com Group (9961.HKEX) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates when the international platform stops costing money and starts printing it. Sustained 40%-plus international growth reaching contribution breakeven, combined with inbound volumes riding visa-free policy, lifts group adjusted EBITDA margin back above 33% just as domestic take rate stabilises at its new floor. Segment disclosure then forces a sum-of-the-parts valuation against global OTA peers, while USD 5bn of buybacks shrinks the float into the re-rating. Compounding follows.

The bear case activates if the remedy proves to be the first regulatory bill, not the last. Meituan and Douyin exploit the unlocked hotel supply, domestic take rate keeps sliding, and Trip.com answers with subsidies that consume the international investment budget simultaneously. Adjusted EBITDA stagnates near RMB 18bn while a further SAMR action on flights lands. The cash pile then reads as a trapped asset rather than optionality, and the multiple compresses toward distressed China-platform levels.

The crowd reads a 7.6x trailing multiple and a 48% drawdown from the January 2026 peak of HKD 613 as a fine-shaped bargain: nineteen buys, no sells, an average target of HKD 476 [15][14]. The anchoring bias is the headline earnings base, which conceals that over 60% of 2025 profit came from the one-off MakeMyTrip disposal [12]. Consensus treats the remedy as an event, not a regime.

Mildly underpriced, but not for the bulls' reason. The crowd overestimates the earnings base and underestimates the asset base. Normalising away the CNY 19.9bn disposal gain and adding back the non-deductible penalty leaves roughly CNY 11.5-12bn of core TTM earnings, so the shares trade near 15x, not 7.6x [11][12]. The blind spot is the other direction: against reported cash near RMB 105.8bn [19], the operating business capitalises around 7x adjusted EBITDA while its international leg compounds above 50% [8].

The decisive trigger is the first clean post-remedy comparison, the Q1-Q2 2027 prints that lap both the pricing-tool removal and the penalty charge. Domestic take rate stabilising while adjusted EBITDA margin re-expands would reset the narrative. The first observable sign is G&A returning toward 7% of revenue.